Sage Therapeutics Inc (SAGE)
15.20
-0.13
(-0.85%)
USD |
NASDAQ |
Apr 16, 10:37
Sage Therapeutics Normalized PE Ratio
Normalized PE Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Normalized PE Ratio Data
| Date | Value |
|---|---|
| December 30, 2021 | -- |
| December 29, 2021 | -- |
| December 28, 2021 | -- |
| December 27, 2021 | -- |
| December 23, 2021 | -- |
| December 22, 2021 | -- |
| December 21, 2021 | -- |
| December 20, 2021 | -- |
| December 17, 2021 | -- |
| December 16, 2021 | -- |
| December 15, 2021 | -- |
| December 14, 2021 | -- |
| December 13, 2021 | -- |
| December 10, 2021 | -- |
| December 09, 2021 | -- |
| December 08, 2021 | -- |
| December 07, 2021 | -- |
| December 06, 2021 | -- |
| December 03, 2021 | -- |
| December 02, 2021 | -- |
| December 01, 2021 | -- |
| November 30, 2021 | -- |
| November 29, 2021 | -- |
| November 26, 2021 | -- |
| November 24, 2021 | -- |
| Date | Value |
|---|---|
| November 23, 2021 | -- |
| November 22, 2021 | -- |
| November 19, 2021 | -- |
| November 18, 2021 | -- |
| November 17, 2021 | -- |
| November 16, 2021 | -- |
| November 15, 2021 | -- |
| November 12, 2021 | -- |
| November 11, 2021 | -- |
| November 10, 2021 | -- |
| November 09, 2021 | -- |
| November 08, 2021 | -- |
| November 05, 2021 | -- |
| November 04, 2021 | -- |
| November 03, 2021 | -- |
| November 02, 2021 | -- |
| November 01, 2021 | -- |
| October 29, 2021 | -- |
| October 28, 2021 | -- |
| October 27, 2021 | -- |
| October 26, 2021 | -- |
| October 25, 2021 | -- |
| October 22, 2021 | -- |
| October 21, 2021 | -- |
| October 20, 2021 | -- |
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.